TRAX Stock: Price, Earnings History and SEC Filings
First Tracks Biotherapeutics, Inc. (TRAX) last traded at $45.08, down 0.33% on the latest session and up 27.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.95 against an analyst estimate of $-0.74, a miss of 28.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TRAX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 12, 2026 | $-0.95 | $-0.74 | -28.38% |
TRAX beat the analyst EPS estimate in 0 of its last 1 reported quarters. Source: Nasdaq.
Latest SEC filings for TRAX
- S-1 · Oct 26, 2026
- 8-K · Oct 20, 2026Material agreement, Financial statements and exhibits
- 8-K · Oct 15, 2026Material agreement, Unregistered share sale, Regulation FD disclosure
- 8-K · Oct 13, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 424B3 · Aug 13, 2026
- 10-Q · Aug 12, 2026
- 8-K · Aug 12, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 22, 2026Material agreement
- 424B3 · May 15, 2026
- 424B3 · May 14, 2026
Insider filing activity
TRAX insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TRAX news
No recent headlines found. The live terminal has the full news feed.
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. (TRAX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.